NASDAQ:ALPN - Alpine Immune Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$9.03 -0.29 (-3.11 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$9.32
Today's Range$9.00 - $9.30
52-Week Range$6.85 - $12.87
Volume52,600 shs
Average Volume19,904 shs
Market Capitalization$133.89 million
P/E Ratio-7.53
Dividend YieldN/A
Beta0.5

About Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences logoAlpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545

Debt

Debt-to-Equity Ratio0.05
Current Ratio26.70
Quick Ratio26.71

Price-To-Earnings

Trailing P/E Ratio-7.53
Forward P/E Ratio-4.96
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.73 million
Price / Sales72.29
Cash FlowN/A
Price / CashN/A
Book Value$5.34 per share
Price / Book1.69

Profitability

EPS (Most Recent Fiscal Year)($1.20)
Net Income$-7,780,000.00
Net MarginsN/A
Return on Equity-20.70%
Return on Assets-19.05%

Miscellaneous

Employees38
Outstanding Shares13,850,000

Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences (NASDAQ:ALPN) posted its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.01. The biotechnology company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.13 million. View Alpine Immune Sciences' Earnings History.

What price target have analysts set for ALPN?

2 brokerages have issued 12 month target prices for Alpine Immune Sciences' shares. Their predictions range from $13.00 to $17.00. On average, they expect Alpine Immune Sciences' stock price to reach $15.00 in the next twelve months. View Analyst Ratings for Alpine Immune Sciences.

Who are some of Alpine Immune Sciences' key competitors?

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the folowing people:
  • Dr. Mitchell H. Gold M.D., Exec. Chairman & CEO (Age 50)
  • Dr. Jay R. Venkatesan M.D., Ph.D., Pres and Director (Age 46)
  • Dr. Stanford Peng M.D., Ph.D., Exec. VP of R&D and Chief Medical Officer (Age 47)
  • Mr. Paul Rickey, Sr. VP & CFO (Age 39)
  • Mr. Ryan Swanson, Co-Founder

Has Alpine Immune Sciences been receiving favorable news coverage?

Media headlines about ALPN stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alpine Immune Sciences earned a coverage optimism score of 0.07 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 47.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (0.52%). Company insiders that own Alpine Immune Sciences stock include Bvf Partners L P/Il, David Malcom Rodman, Janice Troha, Jon Congleton, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Institutional Ownership Trends for Alpine Immune Sciences.

Which major investors are buying Alpine Immune Sciences stock?

ALPN stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. Company insiders that have bought Alpine Immune Sciences stock in the last two years include Bvf Partners L P/Il, Janice Troha, Jon Congleton, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Insider Buying and Selling for Alpine Immune Sciences.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $9.03.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $133.89 million and generates $1.73 million in revenue each year. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Alpine Immune Sciences employs 38 workers across the globe.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]


MarketBeat Community Rating for Alpine Immune Sciences (ALPN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alpine Immune Sciences (NASDAQ:ALPN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Alpine Immune Sciences in the last 12 months. Their average twelve-month price target is $15.00, suggesting that the stock has a possible upside of 66.11%. The high price target for ALPN is $17.00 and the low price target for ALPN is $13.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 3.003.002.502.33
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.00$17.00$17.00$7.3125
Price Target Upside: 66.11% upsideN/A543.94% upside176.99% upside

Alpine Immune Sciences (NASDAQ:ALPN) Consensus Price Target History

Price Target History for Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences (NASDAQ:ALPN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2018WedbushInitiated CoverageOutperform$13.00HighView Rating Details
7/27/2017Ladenburg ThalmannInitiated CoverageBuy ➝ Buy$17.00LowView Rating Details
4/19/2017CowenReiterated RatingHoldMediumView Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$30.00 ➝ $6.00N/AView Rating Details
11/29/2016Raymond JamesDowngradeOutperform ➝ Market PerformN/AView Rating Details
11/29/2016Robert W. BairdDowngradeOutperform ➝ Neutral$29.00 ➝ $3.00N/AView Rating Details
11/29/2016Stifel NicolausDowngradeBuy ➝ Hold$16.00 ➝ $3.25N/AView Rating Details
8/30/2016Piper Jaffray CompaniesReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Alpine Immune Sciences (NASDAQ:ALPN) Earnings History and Estimates Chart

Earnings by Quarter for Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences (NASDAQ:ALPN) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.82 EPS
Next Year EPS Consensus Estimate: $-2.19 EPS

Alpine Immune Sciences (NASDAQ ALPN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018Q1 2018($0.3950)($0.3830)$0.13 million$0.32 millionViewN/AView Earnings Details
3/28/2018Q4 2017($0.3650)($0.33)$0.13 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.62)($0.19)$0.13 millionViewN/AView Earnings Details
7/21/2017Q2 2017($0.96)($0.72)ViewN/AView Earnings Details
5/9/2017Q1 2017($2.24)($2.24)$29.98 millionViewN/AView Earnings Details
2/13/2017Q4 16($0.55)($0.50)ViewN/AView Earnings Details
11/7/2016Q3($0.59)($0.48)ViewN/AView Earnings Details
8/1/2016Q2($0.52)($0.55)ViewN/AView Earnings Details
5/2/2016Q1 16($0.44)($0.51)ViewN/AView Earnings Details
2/29/2016Q4 15($0.3570)($0.42)ViewN/AView Earnings Details
11/2/2015Q3 15($0.39)($0.39)ViewN/AView Earnings Details
8/3/2015Q2 2015($0.40)($1.41)ViewN/AView Earnings Details
4/18/2012$0.61$0.61ViewN/AView Earnings Details
2/2/2012$0.47$0.73ViewN/AView Earnings Details
10/26/2011$0.68$0.73ViewN/AView Earnings Details
7/11/2011$0.77$0.79ViewN/AView Earnings Details
4/27/2011$1.03$1.04ViewN/AView Earnings Details
1/31/2011$0.94$1.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Alpine Immune Sciences (NASDAQ:ALPN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Alpine Immune Sciences (NASDAQ ALPN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 69.00%
Institutional Ownership Percentage: 58.03%
Insider Trading History for Alpine Immune Sciences (NASDAQ:ALPN)
Institutional Ownership by Quarter for Alpine Immune Sciences (NASDAQ:ALPN)

Alpine Immune Sciences (NASDAQ ALPN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/20/2017Value Fund L P BiotechnologyInsiderBuy17,806$2.25$40,063.50View SEC Filing  
6/7/2017Bvf Partners L P/IlMajor ShareholderBuy36,900$2.28$84,132.00View SEC Filing  
6/7/2017Value Fund L P BiotechnologyInsiderBuy72,650$2.29$166,368.50View SEC Filing  
6/5/2017Bvf Partners L P/IlMajor ShareholderBuy35,750$2.29$81,867.50View SEC Filing  
5/31/2017Value Fund L P BiotechnologyInsiderBuy47,000$2.27$106,690.00View SEC Filing  
5/19/2017Value Fund L P BiotechnologyInsiderBuy78,858$2.30$181,373.40View SEC Filing  
5/11/2017Value Fund L P BiotechnologyInsiderBuy109,034$2.32$252,958.88View SEC Filing  
5/9/2017Robert E ConwayDirectorBuy5,000$2.34$11,700.0045,000View SEC Filing  
5/8/2017Robert E ConwayDirectorBuy15,000$2.28$34,200.0060,000View SEC Filing  
5/5/2017Janice TrohaEVPBuy10,000$2.34$23,400.0010,000View SEC Filing  
5/5/2017Robert E ConwayDirectorBuy20,000$2.30$46,000.0040,000View SEC Filing  
5/4/2017Robert E ConwayDirectorBuy10,000$2.26$22,600.0020,000View SEC Filing  
1/4/2017David Malcom RodmanEVPSell6,687$2.27$15,179.4918,055View SEC Filing  
12/2/2016R Michael CarruthersEVPBuy24,000$2.09$50,160.0024,000View SEC Filing  
10/4/2016David Malcom RodmanEVPSell5,820$7.96$46,327.2018,056View SEC Filing  
7/5/2016David Malcom RodmanCMOSell5,950$4.66$27,727.0018,055View SEC Filing  
6/16/2016Jon CongletonCEOBuy5,000$3.87$19,350.0020,000View SEC Filing  
3/24/2016Jon CongletonCEOBuy5,000$4.22$21,100.0015,000View SEC Filing  
3/22/2016Jon CongletonCEOBuy5,000$4.38$21,900.0010,000View SEC Filing  
12/11/2015Jon CongletonCEOBuy5,000$8.10$40,500.005,000View SEC Filing  
12/9/2015Robert E ConwayDirectorBuy10,000$8.10$81,000.0010,000View SEC Filing  
6/23/2015James E FlynnInsiderBuy250,000$14.00$3,500,000.00View SEC Filing  
6/22/2015Bay Master Investors (C HawkesMajor ShareholderBuy17,200$14.69$252,668.00View SEC Filing  
6/18/2015Bay Master Investors (C HawkesMajor ShareholderBuy20,400$14.47$295,188.00View SEC Filing  
6/17/2015Global Healthcare Mas JennisonMajor ShareholderBuy26,149$14.00$366,086.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alpine Immune Sciences (NASDAQ ALPN) News Headlines

Source:
DateHeadline
Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive InitiationAlpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation
finance.yahoo.com - May 19 at 9:23 AM
Alpine Immune Sciences (ALPN) Receives New Coverage from Analysts at WedbushAlpine Immune Sciences (ALPN) Receives New Coverage from Analysts at Wedbush
www.americanbankingnews.com - May 17 at 5:45 PM
Alpine Immune Sciences (ALPN) Announces Quarterly  Earnings Results, Beats Estimates By $0.02 EPSAlpine Immune Sciences (ALPN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 15 at 9:03 AM
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial ResultsAlpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 14 at 4:29 PM
Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of DirectorsAlpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors
finance.yahoo.com - April 24 at 9:27 AM
Alpine Immune Sciences (ALPN) Lowered to "Sell" at Zacks Investment ResearchAlpine Immune Sciences (ALPN) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 20 at 9:56 AM
ValuEngine Upgrades Alpine Immune Sciences (ALPN) to HoldValuEngine Upgrades Alpine Immune Sciences (ALPN) to Hold
www.americanbankingnews.com - April 15 at 3:27 PM
Alpine Immune Sciences (ALPN) Downgraded to "Sell" at ValuEngineAlpine Immune Sciences (ALPN) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 14 at 1:29 PM
Alpine Immune Sciences (ALPN) Rating Lowered to Strong Sell at ValuEngineAlpine Immune Sciences (ALPN) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 7 at 3:18 PM
Alpine Immune Sciences (ALPN) Announces  Earnings ResultsAlpine Immune Sciences (ALPN) Announces Earnings Results
www.americanbankingnews.com - March 29 at 7:38 AM
BRIEF-Alpine Immune Sciences Provides Corporate Update And Reports Full Year 2017 Financial ResultsBRIEF-Alpine Immune Sciences Provides Corporate Update And Reports Full Year 2017 Financial Results
www.reuters.com - March 28 at 9:44 AM
Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual MeetingAlpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual Meeting
finance.yahoo.com - March 22 at 9:44 AM
-$0.44 EPS Expected for Alpine Immune Sciences, Inc. (ALPN) This Quarter-$0.44 EPS Expected for Alpine Immune Sciences, Inc. (ALPN) This Quarter
www.americanbankingnews.com - March 18 at 11:08 PM
Alpine Immune Sciences to Present at Cowen 38th Annual Health Care ConferenceAlpine Immune Sciences to Present at Cowen 38th Annual Health Care Conference
finance.yahoo.com - February 27 at 5:02 PM
Alpine Immune Sciences, Inc. (ALPN) Given Consensus Rating of "Hold" by AnalystsAlpine Immune Sciences, Inc. (ALPN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 24 at 3:38 PM
Zacks: Brokerages Anticipate Alpine Immune Sciences, Inc. (ALPN) Will Announce Earnings of -$0.44 Per ShareZacks: Brokerages Anticipate Alpine Immune Sciences, Inc. (ALPN) Will Announce Earnings of -$0.44 Per Share
www.americanbankingnews.com - February 13 at 5:24 AM
Alpine Immune Sciences (ALPN) Downgraded by Zacks Investment ResearchAlpine Immune Sciences (ALPN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 16 at 4:36 PM
Alpine Immune Sciences (ALPN) Lifted to "Buy" at Zacks Investment ResearchAlpine Immune Sciences (ALPN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 5:50 PM
Alpine Immune Sciences (ALPN) Upgraded to Buy by Zacks Investment ResearchAlpine Immune Sciences (ALPN) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - January 4 at 5:52 PM
Alpine Immune Sciences (ALPN) Cut to Hold at Zacks Investment ResearchAlpine Immune Sciences (ALPN) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 2 at 6:46 PM
ValuEngine Upgrades Alpine Immune Sciences (ALPN) to SellValuEngine Upgrades Alpine Immune Sciences (ALPN) to Sell
www.americanbankingnews.com - December 31 at 12:46 AM
Alpine Immune Sciences (ALPN) Upgraded by Zacks Investment Research to BuyAlpine Immune Sciences (ALPN) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - December 26 at 5:29 PM
Zacks: Analysts Expect Alpine Immune Sciences, Inc. (ALPN) to Post -$0.44 EPSZacks: Analysts Expect Alpine Immune Sciences, Inc. (ALPN) to Post -$0.44 EPS
www.americanbankingnews.com - December 24 at 7:16 PM
Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host DiseaseAlpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease
finance.yahoo.com - December 19 at 8:55 AM
Alpine Immune Sciences, Inc. (ALPN) Receives Average Recommendation of "Hold" from BrokeragesAlpine Immune Sciences, Inc. (ALPN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 11 at 6:28 PM
Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor CellsAlpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells
finance.yahoo.com - December 6 at 9:05 AM
Nivalis Therapeutics, Inc. (ALPN) Given Average Rating of "Hold" by AnalystsNivalis Therapeutics, Inc. (ALPN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 16 at 3:50 PM
Nivalis Therapeutics, Inc. (ALPN) Stock Rating Upgraded by Zacks Investment ResearchNivalis Therapeutics, Inc. (ALPN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM
Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial ResultsAlpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 2:50 AM
Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual MeetingAlpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting
finance.yahoo.com - November 10 at 2:28 PM
Nivalis Therapeutics (ALPN) & The Competition Critical ReviewNivalis Therapeutics (ALPN) & The Competition Critical Review
www.americanbankingnews.com - November 7 at 5:34 AM
Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and InflammationAlpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation
finance.yahoo.com - November 6 at 4:34 PM
Alpine Immune Sciences to Present at Two Upcoming Investor Conferences in NovemberAlpine Immune Sciences to Present at Two Upcoming Investor Conferences in November
finance.yahoo.com - November 1 at 4:12 PM
Zacks Investment Research Lowers Nivalis Therapeutics, Inc. (ALPN) to Strong SellZacks Investment Research Lowers Nivalis Therapeutics, Inc. (ALPN) to Strong Sell
www.americanbankingnews.com - October 26 at 7:24 PM
Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRsAlpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs
finance.yahoo.com - October 23 at 4:51 PM
Nivalis Therapeutics, Inc. (ALPN) Given Consensus Recommendation of "Hold" by AnalystsNivalis Therapeutics, Inc. (ALPN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - October 22 at 4:44 PM
Alpine Immune Sciences Announces Upcoming Scientific PresentationsAlpine Immune Sciences Announces Upcoming Scientific Presentations
finance.yahoo.com - October 16 at 4:35 PM
Impel NeuroPharma names CEOImpel NeuroPharma names CEO
www.bizjournals.com - October 6 at 4:21 AM
Nivalis Therapeutics, Inc. (ALPN) Raised to Buy at Stifel NicolausNivalis Therapeutics, Inc. (ALPN) Raised to Buy at Stifel Nicolaus
www.americanbankingnews.com - September 22 at 7:44 AM
Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual MeetingAlpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting
finance.yahoo.com - September 20 at 3:41 PM
Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare ConferenceAlpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 13 at 4:51 PM
Nivalis Therapeutics, Inc. (ALPN) Receives Average Rating of "Hold" from AnalystsNivalis Therapeutics, Inc. (ALPN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 2 at 7:16 PM
-$0.28 EPS Expected for Nivalis Therapeutics, Inc. (ALPN) This Quarter-$0.28 EPS Expected for Nivalis Therapeutics, Inc. (ALPN) This Quarter
www.americanbankingnews.com - August 15 at 6:06 PM
Strength Seen in FibroGen (FGEN): Stock Soars 48.2%Strength Seen in FibroGen (FGEN): Stock Soars 48.2%
finance.yahoo.com - August 9 at 3:55 PM
Nivalis Therapeutics, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from BrokeragesNivalis Therapeutics, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 8 at 6:44 PM
Corcept (CORT) Looks Good: Stock Moves Up 8.8% in SessionCorcept (CORT) Looks Good: Stock Moves Up 8.8% in Session
finance.yahoo.com - August 3 at 4:45 PM
Alpine Immune Sciences, Inc. (ALPN) Now Covered by Analysts at Ladenburg Thalmann Financial ServicesAlpine Immune Sciences, Inc. (ALPN) Now Covered by Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - July 27 at 9:24 AM

SEC Filings

Alpine Immune Sciences (NASDAQ:ALPN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alpine Immune Sciences (NASDAQ:ALPN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alpine Immune Sciences (NASDAQ ALPN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.